FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 431 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... June 20, 2020 Opinion: ‘The UK must be more ambitious than just clearing the... May 24, 2021 Seeing a Promising Future for Progress against Childhood Cancer September 16, 2021 Nivolumab Injections Could Make Treatment Easier for More People with Cancer March 13, 2024 Load more HOT NEWS New on NCI’s Websites for March 2023 Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... Techniques for Successful Glucose Daddies and Babies Relationships Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with...
